In-Vitro Analysis of Glucose and Quercetin Effects on M-TOR and Nrf-2 Expression in HepG2 Cell Line (Diabetes and Cancer Connection)
Overview
Oncology
Affiliations
Some types of cancers show a strong relationship with diabetes and play a central role in mortality in the patient population suffering from diabetes mellitus. In this study, HepG2 cells have been used to investigate the toxic effects of hyperglycemia and/or quercetin (Q) on mammalian target of rapamycin (m-TOR) and nuclear factor erythroid 2-related factor 2 (Nrf-2) expression as central molecules involved in cancer. HepG2 cells were cultured with different concentrations of glucose (5.5, 30, and 50 mM) and/or Q (25 µM) for 48 and 72 h. Effects of glucose and/or Q on m-TOR and Nrf-2 expression were assayed by quantitative real-time PCR (qRT-PCR). qRT-PCR results revealed that 30 and 50 mM of glucose increased m-TOR expression at 48 h, although after 72 h, only 30 mM had an increasing effect. At 50 mM, glucose-induced Nrf-2 gene expression after both 48 and 72 h. The results also showed that 25 µM of Q reduced m-TOR and Nrf-2 expression at both 30 and 50 mM after 48 and 72 h incubation. Q has potential effects on reducing oxidative stress caused by hyperglycemia and during diabetes may be able to modulate some carcinogenic signaling pathways.
Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer.
Meng S, Cao Y, Lu L, Li X, Sun S, Jiang F Breast Cancer (Dove Med Press). 2024; 16:993-1004.
PMID: 39720358 PMC: 11668317. DOI: 10.2147/BCTT.S494901.
Flavonoids from genus and their biological activities.
Mamuaja M, Herlina T, Rumampuk R, Maksum I, Rukayadi Y ADMET DMPK. 2024; 12(6):843-879.
PMID: 39713250 PMC: 11661801. DOI: 10.5599/admet.2442.
Notch Signaling Suppression by Golden Phytochemicals: Potential for Cancer Therapy.
Zenjanab M, Hashemzadeh N, Alimohammadvand S, Sharifi-Azad M, Abdolahinia E, Jahanban-Esfahlan R Adv Pharm Bull. 2024; 14(2):302-313.
PMID: 39206407 PMC: 11347744. DOI: 10.34172/apb.2024.035.
Zhang L, Xu L, Tang F, Liu D, Zhao X, Zhang J J Pharm Anal. 2024; 14(6):100930.
PMID: 39005843 PMC: 11245930. DOI: 10.1016/j.jpha.2023.12.020.
Exploring monocarboxylate transporter inhibition for cancer treatment.
Koltai T, Fliegel L Explor Target Antitumor Ther. 2024; 5(1):135-169.
PMID: 38464385 PMC: 10918235. DOI: 10.37349/etat.2024.00210.